Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.

You may also be interested in...



Emerging Markets Slowdown Trips Up Lilly’s 2014 Revenue Estimates

Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.

As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader

With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.

Pinning Hopes On A Wider Offering, Boehringer-Lilly Launch DPP-4 Trajenta In A Crowded India Market

A 30% annual growth in the anti-diabetes market is fueling new launches in India, but competition is getting tougher.

Related Content

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel